Development of a high-throughput assay for screening of γ-secretase inhibitor with endogenous human, mouse or drosophila γ-secretase

Molecules

Volumn 14, Issue 9, 2009, Pages 3589-3599

  Wang, Lie Feng ^a   Zhang, Ru ^a   Xie, Xin ^a,b  

^a TONGJI UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Secretase inhibitor; Fluorogenic substrate; High throughput screening

Indexed keywords

ENZYME INHIBITOR; SECRETASE;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL LINE; CHEMISTRY; DOSE RESPONSE; DROSOPHILA MELANOGASTER; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; METHODOLOGY; MOLECULAR GENETICS; MOUSE;

AMINO ACID SEQUENCE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DROSOPHILA MELANOGASTER; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MOLECULAR SEQUENCE DATA;

EID: 70349559753     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules14093589     Document Type: Article

References (25)

1. Tanzi, R.E. The synaptic Aβ hypothesis of Alzheimer disease. Nat. Neurosci. 2005, 8, 977-979.
2. Iwatsubo, T.; Odaka, A.; Suzuki, N.; Mizusawa, H.; Ihara, Y. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43). Neuron 1994, 13, 45-53.
3. Marlow, L.; Canet, R.M.; Haugabook, S.J.; Hardy, J.A.; Lahiri, D.K.; Sambamurti, K. APH1, PEN2, and Nicastrin increase Abeta levels and gamma-secretase activity. Biochem. Biophys. Res. Commun. 2003, 305, 502-509.
4. Li, Y.M.; Lai, M.T.; Xu, M.; Huang, Q.; DiMuzio-Mower, J.; Sardana, M.K.; Shi, X.P.; Yin, K.C.; Shafer, J.A.; Gardell, S.J. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc. Natl. Acad. Sci. USA 2000, 97, 6138-6143.
5. Dovey, H.F.; John, V.; Anderson, J.P.; Chen, L.Z.; De, S.A.P.; Fang, L.Y.; Freedman, S.B.; Folmer, B.; Goldbach, E.; Holsztynska, E.J. Hu, K.L.; Johnson-Wood, K.L.; Kennedy, S.L.; Kholodenko, D.; Knops, J.E.; Latimer, L.H.; Lee, M.; Liao, Z.; Lieberburg, I.M.; Motter, R.N.; Mutter, L.C.; Nietz, J.; Quinn, K.P.; Sacchi, K.L.; Seubert, P.A.; Shopp, G.M.; Thorsett, E.D.; Tung, J.S.; Wu, J.; Yang, S.; Yin, C.T.; Schenk, D.B.; May, P.C.; Altstiel, L.D.; Bender, M.H.; Boggs, L.N.; Britton, T.C.; Clemens, J.C.; Czilli, D.L.; Dieckman-McGinty, D.K.; Droste, J.J.; Fuson, K.S.; Gitter, B.D.; Hyslop, P.A.; Johnstone, E.M.; Li, W.Y.; Little, S.P.; Mabry, T.E.; Miller, F.D.; Audia, J.E. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 2001, 173-181.
6. Shearman, M.S.; Beher, D.; Clarke, E.E.; Lewis, H.D.; Harrison, T.; Hunt, P.; Nadin, A.; Smith, A.L.; Stevenson, G.; Castro, J.L. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry 2000, 39, 8698-8704.
7. Wolfe, M.S. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics 2008, 5, 391-398.
8. Rafii, M.S.; Aisen, P.S. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009, 7, 7.
9. Beher, D.; Wrigley, J.D.; Nadin, A.; Evin, G.; Masters, C.L.; Harrison, T.; Castro, J.L.; Shearman, M.S. Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma -secretase inhibitor: Implications for presenilin biology. J. Biol. Chem. 2001, 276, 45394-45402.
10. Vandermeeren, M.; Geraerts, M.; Pype, S.; Dillen, L.; Van Hove, C.; Mercken, M. The functional gamma-secretase inhibitor prevents production of amyloid beta 1-34 in human and murine cell lines. Neurosci. Lett. 2001, 315, 145-148.
11. Berezovska, O.; Jack, C.; McLean, P.; Aster, J.C.; Hicks, C.; Xia, W.; Wolfe, M.S.; Kimberly, W.T.; Weinmaster, G.; Selkoe, D.J.; Hyman, B.T. Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling. J. Neurochem. 2000, 75, 583-593.
12. Farmery, M.R.; Tjernberg, L.O.; Pursglove, S.E.; Bergman, A.; Winblad, B.; Naslund, J. Partial purification and characterization of gamma-secretase from post-mortem human brain. J. Biol. Chem. 2003, 278, 24277-24284.
13. Xu, M.; Lai, M.T.; Huang, Q.; DiMuzio-Mower, J.; Castro, J.L.; Harrison, T.; Nadin, A.; Neduvelil, J.G.; Shearman, M.S.; Shafer, J.A.; Gardell, S.J.; Li, Y.M. gamma-Secretase: Characterization and implication for Alzheimer disease therapy. Neurobiol. Aging 2002, 23, 1023-1030.
14. Zhang, J.H.; Chung, T.D.Y.; Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4, 67-73.
15. Wang, J.; Xie, X. Development of a quantitative, cell-based, high-content screening assay for epidermal growth factor receptor modulators. Acta Pharmacol. Sin. 2007, 28, 1698-1704.
16. Xu, X. gamma-Secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. J. Alzheimers Dis. 2009, 16, 211-224.
17. Morohashi, Y.; Kan, T.; Tominari, Y.; Fuwa, H.; Okamura, Y.; Watanabe, N.; Sato, C.; Natsugari, H.; Fukuyama, T.; Iwatsubo, T.; Tomita, T. C-terminal fragment of presenilin is the moleculartarget of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl] -S-phenylglycine t-butyl ester). J. Biol. Chem. 2006, 281, 14670-14676.
18. Shiraishi, H.; Sai, X.; Wang, H.Q.; Maeda, Y.; Kurono, Y.; Nishimura, M.; Yanagisawa, K.; Komano, H. PEN-2 enhances gamma-cleavage after presenilin heterodimer formation. J. Neurochem. 2004, 90, 1402-1413.
19. Milano, J.; McKay, J.; Dagenais, C.; Foster-Brown, L.; Pognan, F.; Gadient, R.; Jacobs, R.T.; Zacco, A.; Greenberg, B.; Ciaccio, P.J. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. 2004, 82, 341-358.
20. Esler, W.P.; Kimberly, W.T.; Ostaszewski, B.L.; Ye, W.; Diehl, T.S.; Selkoe, D.J.; Wolfe, M.S. Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc. Natl. Acad. Sci. USA 2002, 99, 2720-2725.
21. Rishton, G.M.; Retz, D.M.; Tempest, P.A.; Novotny, J.; Kahn, S.; Treanor, J.J.; Lile, J.D.; Citron, M. Fenchylamine sulfonamide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: Potential small-molecule therapeutic agents for the treatment of Alzheimer's disease. J. Med. Chem. 2000, 43, 2297-2299.
22. Takasugi, N.; Takahashi, Y.; Morohashi, Y.; Tomita, T.; Iwatsubo, T. The mechanism of gamma-secretase activities through high molecular weight complex formation of presenilins is conserved in Drosophila melanogaster and mammals. J. Biol. Chem. 2002, 277, 50198-50205.
23. Micchelli, C.A.; Esler, W.P.; Kimberly, W.T.; Jack, C.; Berezovska, O.; Kornilova, A.; Hyman, B.T.; Perrimon, N.; Wolfe, M.S. Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J. 2003, 17, 79-81.
24. Best, J.D.; Smith, D.W.; Reilly, M.A.; O'Donnell, R.; Lewis, H.D.; Ellis, S.; Wilkie, N.; Rosahl, T.W.; Laroque, P.A.; Boussiquet-Leroux, C.; Churcher, I.; Atack, J.R.; Harrison, T.; Shearman, M.S. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]- 1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J. Pharmacol. Exp. Ther. 2007, 320, 552-558.
25. Hyde, L.A.; McHugh, N.A.; Chen, J.; Zhang, Q.; Manfra, D.; Nomeir, A.A.; Josien, H.; Bara, T.; Clader, J.W.; Zhang, L.; Parker, E.M.; Higgins, G.A. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl- 6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J. Pharmacol. Exp. Ther. 2006, 319, 1133-1143.